Apr 30, 2020
SRP-9001 [Sarepta Therapeutics] Emerging Insights and Market Forecast to 2030
Dec 13, 2019
MDA Celebrates FDA Approval of Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping
Dec 12, 2019
FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation
Sep 04, 2019
SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019
Aug 22, 2019
Avidity Biosciences Adds Drug Development Veterans Edward Kaye and Noreen Henig to Board of Directors
Jul 02, 2019
AskBio's Perspective on Pfizer's 1b Clinical Trial Results on Duchenne MD Gene Therapy
Apr 15, 2019
Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with gene therapy leader Sarepta Therapeutics
Sep 07, 2018
Parent Project Muscular Dystrophy and Sarepta Therapeutics Partner to Launch Duchenne Outcomes Research Interchange, a Patient-Data Warehouse Serving the Entire Duchenne Community
Jun 25, 2018
Decode Duchenne Announces 1,000th Patient Application
Jun 20, 2018
Biotech Resurgent Growth Championed by Cancer Research and Clinical Trial Advancements
May 07, 2018
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
Mar 16, 2018
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology
Jan 29, 2018
Worldwide Duchenne Muscular Dystrophy Treatment Market to Reach US$ 10,664.5 Mn by 2026 - Persistence Market Research
Jan 25, 2018
Biotechnology Companies Prepared for a Big 2018
Dec 19, 2017
Pre-Market Technical Scan on Biotech Equities -- Portola Pharmaceuticals, Sarepta Therapeutics, Pacific Biosciences of California, and bluebird bio
Jun 23, 2017
Technical Research on Biotech Equities -- Celsion, Sarepta Therapeutics, BioMarin Pharma, and ContraVir Pharma